Tazolol
Tazolol is a specific β-adrenergic antagonist (IC50: 700 nM for (-) isoproterenol-elicited accumulation of cyclic AMP in rat cortical slices). Tazolol produces a significant and sustained increase in cardiac output and stroke volume. Tazolol can be used in the research of heart failure.
For research use only. We do not sell to patients.
- CAS No.: 39832-48-9
- Formula: C9H16N2O2S
- Molecular Weight:216.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Adrenergic Receptor Isoforms
More
Biological Activity
Description
|
β-adrenoceptor |
Chemical Information
-
CAS No. 39832-48-9
-
Molecular Weight 216.30
-
Formula C9H16N2O2S
-
SMILES
OC(CNC(C)C)COC1=NC=CS1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
[1]. Skolnick, et al. Blockade of central beta-adrenergic receptors by tazolol (1-isopropylamino-3-(2-thiazoloxy)-2-propanol). Life Sci. 1977 Dec 1;21(11):1655-63. [Content Brief]
[2]. Buckley HT, et al. Circulatory effects of tazolol in experimental myocardial infarction. Am J Cardiol. 1975 May;35(5):619-25. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tazolol Related Classifications
HY-149796 Related Classifications
Powered by Bioz